Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Toni M. Brand, Stefan Hartmann, Neil E. Bhola, Hua Li, Yan Zeng, Rachel A. O'Keefe, Max V. Ranall, Sourav Bandyopadhyay, Margaret Soucheray, Nevan J. Krogan, Carolyn Kemp, Umamaheswar Duvvuri, Theresa LaVallee, Daniel E. Johnson, Michelle A. Ozbun, Julie E. Bauman, Jennifer R. Grandis

Cancer Res (2022) 82 (17): 3188.

https://doi.org/10.1158/0008-5472.CAN-22-1307

Published: 02 September 2022

View articletitled, Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Journal Articles

Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Cancer Res (2022) 82 (17): 3187.

https://doi.org/10.1158/0008-5472.CAN-22-1308

Published: 02 September 2022

View articletitled, Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Journal Articles

BET Inhibition Overcomes Receptor Tyrosine Kinase–Mediated Cetuximab Resistance in HNSCC

Brandon Leonard, Toni M. Brand, Rachel A. O'Keefe, Eliot D. Lee, Yan Zeng, Jacquelyn D. Kemmer, Hua Li, Jennifer R. Grandis, Neil E. Bhola

Cancer Res (2018) 78 (15): 4331–4343.

https://doi.org/10.1158/0008-5472.CAN-18-0459

Published: 31 July 2018

View articletitled, BET Inhibition Overcomes Receptor Tyrosine Kinase–Mediated Cetuximab Resistance in HNSCC

Includes: Supplementary data

Journal Articles

Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Cancer Res (2018) 78 (9): 2383–2395.

https://doi.org/10.1158/0008-5472.CAN-17-1672

Published: 30 April 2018

View articletitled, Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Includes: Supplementary data

Journal Articles

Abstract 4108: Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma

Rachel A. O'Keefe, Neil Bhola, Toni M. Brand, Yan Zeng, Daniel E. Johnson, Jennifer R. Grandis

Cancer Res (2017) 77 (13_Supplement): 4108.

https://doi.org/10.1158/1538-7445.AM2017-4108

Published: 01 July 2017

View articletitled, Abstract 4108: Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma

Journal Articles

Abstract 4176: Targeting TAM family members with antibody or small molecule inhibitors enhances therapeutic modalities of HNSCC

Nellie K. Black, Mari Iida, Tamara S. Rodems, Toni M. Brand, Randall J. Kimple, Deric L. Wheeler

Cancer Res (2017) 77 (13_Supplement): 4176.

https://doi.org/10.1158/1538-7445.AM2017-4176

Published: 01 July 2017

View articletitled, Abstract 4176: Targeting TAM family members with antibody or small molecule inhibitors enhances therapeutic modalities of HNSCC

Journal Articles

Abstract 3333: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

Toni M. Brand, Mari Iida, Kelsey L. Corrigan, Cara M. Braverman, John P. Coan, Bailey G. Flanigan, Andrew P. Stein, Ravi Salgia, Jana Rolff, Randall J. Kimple, Deric L. Wheeler

Cancer Res (2017) 77 (13_Supplement): 3333.

https://doi.org/10.1158/1538-7445.AM2017-3333

Published: 01 July 2017

View articletitled, Abstract 3333: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

Journal Articles

Abstract 247: Understanding the role of tyrosine 1101 in the nuclear translocation of the epidermal growth factor receptor

Bailey G. Flanigan, Mari Iida, Toni M. Brand, Deric L. Wheeler

Cancer Res (2016) 76 (14_Supplement): 247.

https://doi.org/10.1158/1538-7445.AM2016-247

Published: 15 July 2016

View articletitled, Abstract 247: Understanding the role of tyrosine 1101 in the nuclear translocation of the epidermal growth factor receptor

Journal Articles

AXL Mediates Resistance to Cetuximab Therapy

Toni M. Brand, Mari Iida, Andrew P. Stein, Kelsey L. Corrigan, Cara M. Braverman, Neha Luthar, Mahmoud Toulany, Parkash S. Gill, Ravi Salgia, Randall J. Kimple, Deric L. Wheeler

Cancer Res (2014) 74 (18): 5152–5164.

https://doi.org/10.1158/0008-5472.CAN-14-0294

Published: 14 September 2014

View articletitled, AXL Mediates Resistance to Cetuximab Therapy

Includes: Supplementary data

Journal Articles

Abstract 5646: Overcoming acquired resistance to cetuximab by dual targeting of HER family members using antibody based therapy.

Mari Iida, Toni M. Brand, Megan M. Starr, Neha Luthar, Matthew J. Wleklinski, Deric L. Wheeler

Cancer Res (2013) 73 (8_Supplement): 5646.

https://doi.org/10.1158/1538-7445.AM2013-5646

Published: 15 April 2013

View articletitled, Abstract 5646: Overcoming acquired resistance to cetuximab by dual targeting of HER family members using antibody based therapy.

Journal Articles

Abstract 4276: Mapping C-terminal transactivation domains of nuclear HER family receptor tyrosine kinases.

Toni M. Brand, Mari Iida, Matthew J. Wleklinski, Neha Luthar, Megan M. Starr, Deric L. Wheeler

Cancer Res (2013) 73 (8_Supplement): 4276.

https://doi.org/10.1158/1538-7445.AM2013-4276

Published: 15 April 2013

View articletitled, Abstract 4276: Mapping C-terminal transactivation domains of nuclear HER family receptor tyrosine kinases.

Journal Articles

Abstract LB-219: Nuclear EGFR serves as a functional molecular target in triple-negative breast cancer.

Toni M. Brand, Mari Iida, Neha Luthar, Matthew Wleklinski, Kellie Kostopoulos, Deric L. Wheeler

Cancer Res (2013) 73 (8_Supplement): LB-219.

https://doi.org/10.1158/1538-7445.AM2013-LB-219

Published: 15 April 2013

View articletitled, Abstract LB-219: Nuclear EGFR serves as a functional molecular target in triple-negative breast cancer.

Journal Articles

Abstract 5726: Human epidermal growth factor 3 (HER3) blockade with U3-1287/AMG888 modulates radiosensitivity in the lung and head and neck carcinomas

Chunrong Li, Mari Iida, Shyhmin Huang, Eric A. Armstrong, Toni M. Brand, Charlie R. Peet, Deric L. Wheeler

Cancer Res (2012) 72 (8_Supplement): 5726.

https://doi.org/10.1158/1538-7445.AM2012-5726

Published: 15 April 2012

View articletitled, Abstract 5726: Human epidermal growth factor 3 (HER3) blockade with U3-1287/AMG888 modulates radiosensitivity in the lung and head and neck carcinomas

Journal Articles

Abstract 726: Erlotinib overcomes acquired resistance to cetuximab

Toni M. Brand, Emily F. Dunn, Mari Iida, Rebecca Myers, Chunrong Li, Deric L. Wheeler

Cancer Res (2011) 71 (8_Supplement): 726.

https://doi.org/10.1158/1538-7445.AM2011-726

Published: 15 April 2011

View articletitled, Abstract 726: Erlotinib overcomes acquired resistance to cetuximab

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

BET Inhibition Overcomes Receptor Tyrosine Kinase–Mediated Cetuximab Resistance in HNSCC

Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Abstract 4108: Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma

Abstract 4176: Targeting TAM family members with antibody or small molecule inhibitors enhances therapeutic modalities of HNSCC

Abstract 3333: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

Abstract 247: Understanding the role of tyrosine 1101 in the nuclear translocation of the epidermal growth factor receptor

AXL Mediates Resistance to Cetuximab Therapy

Abstract 5646: Overcoming acquired resistance to cetuximab by dual targeting of HER family members using antibody based therapy.

Abstract 4276: Mapping C-terminal transactivation domains of nuclear HER family receptor tyrosine kinases.

Abstract LB-219: Nuclear EGFR serves as a functional molecular target in triple-negative breast cancer.

Abstract 5726: Human epidermal growth factor 3 (HER3) blockade with U3-1287/AMG888 modulates radiosensitivity in the lung and head and neck carcinomas

Abstract 726: Erlotinib overcomes acquired resistance to cetuximab

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only